title: Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
abstract: Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer. There were 4 CR, 17 PR (objective response rate 28%). Highest response was in soft tissue. CNS toxicity was less than with conventional dose AG (drowsiness 7% v. 31%), although the incidence of rash was equivalent. Previous responders to tamoxifen had a higher response (33%) than previous non-responders (9%). The lower toxicity and maintained efficacy suggest that this should be the standard dosage regimen.
mesh_terms: D000368:Aged; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008593:Menopause; D011379:Prognosis
chemical_list: D000616:Aminoglutethimide; D006854:Hydrocortisone